Advances in pharmacotherapy for the treatment of gout

Robinson, Philip C. and Dalbeth, Nicola (2015) Advances in pharmacotherapy for the treatment of gout. Expert Opinion On Pharmacotherapy, 16 4: 533-546. doi:10.1517/14656566.2015.997213


Author Robinson, Philip C.
Dalbeth, Nicola
Title Advances in pharmacotherapy for the treatment of gout
Journal name Expert Opinion On Pharmacotherapy   Check publisher's open access policy
ISSN 1465-6566
1744-7666
Publication date 2015-03
Year available 2015
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1517/14656566.2015.997213
Volume 16
Issue 4
Start page 533
End page 546
Total pages 14
Place of publication London, United Kingdom
Publisher Informa Healthcare
Collection year 2016
Language eng
Formatted abstract
Introduction: Gout is a common inflammatory arthritis affecting almost 6% of US males and 2% of US females. The central cause of gout is deposition of monosodium urate crystals, and the focus of treatment is aimed at crystal dissolution using urate-lowering therapy.

Areas covered: The review describes the current treatments for urate-lowering therapy including allopurinol, febuxostat, probenecid, benzbromarone and pegloticase. Anti-inflammatory treatment of acute flares and prophylaxis of flares with NSAIDs, colchicine, corticosteroids and anti-IL-1 agents is also reviewed. In addition, drugs in Phase III clinical trials for gout indications are reviewed.

Expert opinion: In the last decade, there has been major progress in the pharmacotherapy of gout. Management guidelines have emphasized the importance of a therapeutic serum urate target for effective gout management. Studies have identified the safe and effective dosing strategies for ‘old’ drugs such as allopurinol and colchicine. New therapeutic agents have been developed and approved for both urate-lowering therapy and anti-inflammatory treatment of acute flares. However, quality of care remains a major challenge in gout management, and strategies to ensure best practice require further focus to ensure that the progress of the last decade translates into clinical benefit for people with gout.




Keyword Allopurinol
Febuxostat
Gout
Pegloticase
Probenecid
Urate
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2016 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 8 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 16 Feb 2015, 13:51:45 EST by Susan Day on behalf of Queensland Brain Institute